All In MedTech

Device Trial Radar · NCT04629157

The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19

Last checked: Nov 20, 2026Latest source record: Nov 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

400

Actual

Start

Nov 5, 2020

Primary completion

Feb 1, 2021

Study completion Feb 1, 2021

Sponsor

Lead sponsor
Alder Hey Children's NHS Foundation TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 16, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 0 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pilot study which aims to assess the validity and applicability of lateral flow assays (LFAs) which can be used as a point of care test for COVID-19. The study will focus on children admitted to hospital or planned to have a procedure for which they require an anaesthetic. RT-PCR is the current gold standard test for COVID-19, but it usually takes approximately 24-48 hours for a test result to be returned which can slow the clinical care given to a patient and can potentially increase the risk of healthcare worker (HWC) exposure to COVID-19. LFAs are a point of care test which can identify children who have a high viral load of COVID-19 and are performed using a more acceptable method of swabbing for children, just inside the nostril. Using LFA potentially enables the identification of infectious children with COVID-19 to aid with immediate care of patients and limiting HWC and other patients' contact with the virus. This study aims to assess the test failure rate and identify reasons for this which can be addressed. It also aims to assess the discomfort of both tests for children, provide a comparison between the time to LCA and RT-PCR result and provide data for a trial to adequately power a prospective trial comparing RT-PCR and LFA.

Conditions

  • This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19
  • Covid19

Interventions

  • Innova Lateral Flow DeviceDevice

    The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acceptability of TestTime frame: Immediately after test on the day of test

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Alder Hey in the Park

    Liverpool, United Kingdom

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.